Nanofilm coating shows excellent biocompatibility, safety.(OBSERVATIONS)

MIV Therapeutics, Vancouver, B.C., a developer of next-generation drug-eluting coatings that inhibit the rejection of implanted medical devices, has announced the successful completion of pilot preclinical studies of hydroxyapatite-coated stents in pig coronary arteries. Over a 28-day safety study, four different formulations of MIVT's biocompatible hydroxyapatite nanofilm coating were evaluated. The nanofilm is ...